cytotoxic T cell

Overview

Cytotoxic T cells, also known as CD8+ T cells, are a subtype of T lymphocytes that play a crucial role in the immune response by directly killing infected or cancerous cells. They recognize and eliminate cells presenting specific antigens through the T-cell receptor (TCR) and are essential for controlling viral infections and tumor growth. Upon activation, cytotoxic T cells proliferate and differentiate into effector cells capable of releasing cytotoxic granules containing perforin and granzymes, which induce apoptosis in target cells. Their functionality is modulated by various factors, including cytokines such as interferon-gamma (IFNG) and interactions with immune checkpoint proteins like PD-1 and CTLA-4.

Focus of Latest Publications

Recent studies have highlighted the pivotal role of cytotoxic T cells in cancer immunotherapy and the tumor microenvironment. For instance, a phase II trial combining pembrolizumab, a PD-1 inhibitor, with paclitaxel and carboplatin in melanoma demonstrated that an objective response was associated with a higher proportion of mature NK cells and CD4 T cells expressing BTLA or LAIR-1, alongside a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline (PMID: 41732954). This underscores the importance of T cell maturation and the immune landscape in therapeutic outcomes.

In another study, the use of splenic dendritic cell-targeting mRNA transfection significantly increased the amounts of IFN-γ+ CD8+ T cells and effector memory CD8+ T cells, suggesting that enhancing antigen presentation can boost cytotoxic T cell responses (PMID: 41737632). Similarly, the combination of L19-TNF with a CD3-based bispecific T-cell engager (TCE) was shown to enhance tumor cell killing and CD8+ T-cell proliferation, indicating that Targeted therapies can synergistically improve T cell-mediated tumor destruction (PMID: 42012522).

Moreover, research has explored the mechanisms of immune evasion in tumors, such as the orchestration of IL-33-mediated M2-like polarization of tumor-associated macrophages, which was linked to reduced infiltration of CD8+ T cells in colorectal cancer models (PMID: 41962054). This highlights the complex interplay between tumor microenvironment factors and cytotoxic T cell activity.

Innovative therapeutic strategies, including the use of biomimetic nanodecoys and programmable DNAzyme nanocatalysts, have been developed to enhance cytotoxic T cell infiltration and activation in tumors (PMID: 42002768; PMID: 41981590). These approaches aim to remodel the immune microenvironment and improve the efficacy of existing immunotherapies, such as checkpoint inhibitors.

Additionally, studies have indicated that androgen receptor signaling can induce CD8+ T-cell dysfunction, which can be reversed by androgen deprivation therapy, further emphasizing the importance of understanding the regulatory mechanisms affecting cytotoxic T cell function in various cancer types (PMID: 41661680).